The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells.

e20099 Background: Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by loss of the tumor suppressor Rb. Chemotherapy and radiation remain the standard of care for SCLC patients but produces severe myelosuppression. Cyclin dependent kinases 4 and 6 (CDK4/6) phosphorylate the Rb protein promoting proliferation by allowing cells to progress through S phase. We hypothesize that CDK4/6 inhibition produces a G1 cell...